Medical organization Journey Medical aims to maintain and boost momentum in EMROSI, with profitability goals set for 2025, as the prescriber base is projected to nearly triple by that time.
Journey Medical Corporation, a leading healthcare company, has recently announced its Q2 2025 financial results, with a particular focus on the performance of its new product, Emrosi.
Financial Highlights
The total revenue for Q2 2025 stood at $15.0 million, marking a significant improvement compared to the previous year. However, the report did not provide information about the overall net product revenue from the prior year.
The financial success of Emrosi was evident, as it generated $2.8 million in its first full quarter of sales. This figure represents a substantial contribution to the overall quarterly revenue. The gross margin for the quarter improved to 67%, up from 61% in the prior year quarter.
Despite the revenue growth, the company incurred a net loss of $3.8 million or $(0.16) per share for Q2 2025. Journey Medical maintained its cash balance at $20.3 million as of June 30, 2025.
Sales and Market Updates
Emrosi has been driving strong prescription growth, with over 12,800 cumulative TRx (total prescriptions) through July 2025. This represents record month-over-month and week-over-week increases in prescriptions.
Payer access for Emrosi has also expanded significantly, covering over 100 million commercial lives in the U.S., up from 54 million in May 2025. This broadened coverage is a testament to the growing acceptance of Emrosi in the market.
Journey Medical Corporation's growing market presence was further reinforced by its inclusion in the Russell 2000® and Russell 3000® Indexes in June 2025.
Future Outlook
Analysts project peak U.S. sales for Emrosi of $500 million, contingent on sustained payer coverage and physician adoption within a $2.3 billion market. Despite competition from established dermatology treatments, Emrosi is gaining traction through patent protection and inclusion in national treatment guidelines.
Claude Maraoui, CEO of EMROSI, announced the first full quarter of the company's market launch. The second quarter net product revenue of EMROSI was reported as $15 million, surpassing the prior year quarter sales, although the exact sales figure for the prior year quarter was not specified. The report did not provide information about the total net product revenue for the second quarter, only the portion attributed to EMROSI sales. However, it is clear that this revenue represents a growth in the company's sales.
[1] Journey Medical Corporation Q2 2025 Earnings Release [2] Seeking Alpha Transcript of Journey Medical Corporation Q2 2025 Earnings Call [3] Yahoo Finance Analyst Estimates for Journey Medical Corporation [4] Business Wire: Journey Medical Corporation Joins Russell 2000® and Russell 3000® Indexes [5] PR Newswire: Emrosi Prescription Growth Continues to Accelerate in Q2 2025
Investing in the healthcare sector could be a strategic move for businesses, given the promising growth of products like Emrosi. The recently announced Q2 2025 financial results of Journey Medical Corporation, a leading healthcare company, showcased a significant improvement in revenue, with Emrosi generating $2.8 million in its first full quarter of sales.
